Combined tumour necrosis factor-  and tumour necrosis factor receptor genotypes could predict rheumatoid arthritis patients' response to anti-TNF-  therapy and explain controversies of studies based on a single polymorphism

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

“…After the full-text review, 10 of these 18 articles were excluded because 2 of them were review articles [16,24], 3 articles had no exact statistics about polymorphisms [25][26][27], 1 reported duplicate data [28], 1 was irrelevant to biological agent [29], 3 were not related to TNFRSF polymorphisms [2,30,31]. Finally, in the current study, 8 eligible studies [32][33][34][35][36][37][38][39] that meet the inclusion criteria were included in our biologic-specific meta-analysis.…”

“…Therefore, seven of the eight studies containing 929 subjects for TNFRSF1B rs1061622 and five of eight studies involving 564 subjects for TNFRSF1A rs767455 were finally analyzed in our meta-analysis. For TNFRSF1B rs1061622, the subjects in three included studies were of RA [36,38,39], two CD [33,34] and the other two of psoriasis [32,37]. As for TNFRSF1A rs767455, two studies were carried out in RA [35,39], two in CD [33,34] and the other one in psoriasis [35] ( Table 2).…”

“…For TNFRSF1B rs1061622, the subjects in three included studies were of RA [36,38,39], two CD [33,34] and the other two of psoriasis [32,37]. As for TNFRSF1A rs767455, two studies were carried out in RA [35,39], two in CD [33,34] and the other one in psoriasis [35] ( Table 2). Different genotyping methods were utilized including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), melting curve-based analysis using LightCycler 480 RealTime PCR System, FRET and big dye chemistry.…”

Tumour necrosis factor α −308G→A polymorphism is not associated with response to TNFα blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis

“…Two meta-analyses, performed by Lee et al in 20066 and O’Rielly et al in 2009,25 including data of 311 and 692 patients, respectively, suggested that patients with RA carrying the rare A allele had a worse response to anti-TNF therapy than those carrying the common G allele. However, these meta-analyses pooled data with varying response criteria and curiously, did not include studies that did not support a significant effect of this polymorphism on anti-TNF response 16 26. Furthermore, the meta-analysis from O’Rielly did not include three recently published studies accounting for 1551 additional patients with RA treated with anti-TNF agents 20–22…”

Patient-tailored therapy in rheumatoid arthritis: an editorial review

“…No single genetic marker that predicts primary response to TNF-antagonists with replication in all cohorts has so far been identified (Table 1) [45][46][47][48][49][50][51][52][53][54][55][56][57][58][59][60][61][62][63][64]. Pharmacogenetic studies in the field are hampered by clinical heterogeneity of the study populations (e.g.…”